Kepatuhan Konsumsi Obat Kelasi Besi dan Kadar Feritin Serum Pasien Talasemia Beta-Mayor di RSUD Al-Ihsan Bandung

Hutari Gustiana, Tito Gunantara, Hilmi Sulaiman Rathomi

Abstract


Kadar feritin serum yang tinggi pada pasien talasemia menimbulkan berbagai komplikasi yang menurunkan kualitas hidup pasien. Kadar tersebut dipengaruhi oleh berbagai hal, salah satunya kepatuhan pasien dalam mengonsumsi obat kelasi besi. Penelitian ini bertujuan mengetahui tingkat kepatuhan konsumsi obat kelasi besi dan kadar feritin serum pada penderita talasemia beta-mayor di RSUD Al-Ihsan Bandung serta hubungan antara keduanya. Penelitian ini merupakan studi cross sectional dengan melibatkan 50 pasien talasemia di RSUD Al-Ihsan Bandung yang dipilih secara consecutive. Data tingkat kepatuhan diukur dengan kuesioner Morisky Medication Adherence Scale-8 (MMAS-8) yang diisi dipandu oleh peneliti, sedangkan data kadar feritin serum didapatkan dari rekam medis pasien. Pengambilan data dilakukan pada bulan Juli–September 2019, data dianalisis menggunakan uji chi square dengan bantuan piranti lunak STATA versi 13. Hasil penelitian menunjukkan mayoritas penderita talasemia beta-mayor di RSUD Al-Ihsan Bandung (60%, IK 45,4–72,9%) memiliki tingkat kepatuhan rendah dalam konsumsi obat kelasi besi dan sebagian besar memiliki kadar feritin serum >2.500 ng/mL (58%, IK 43,5–71,2%). Terdapat hubungan bermakna secara statistik antara tingkat kepatuhan konsumsi obat kelasi besi dan kadar feritin serum pada penderita talasemia beta-mayor di RSUD Al-Ihsan Bandung (p=0,00).

 

DRUG ADHERENCE OF IRON-CHELATING AGENT AND SERUM FERRITIN LEVELS OF BETA-MAJOR THALASSEMIA PATIENTS IN AL-IHSAN HOSPITAL BANDUNG 

High serum ferritin levels in thalassemia patients cause various complications that reduce the quality of life of patients. These levels are influenced by various things, one of which is patient compliance in consuming iron chelation. This study aims to determine the level of compliance with iron chelation drug consumption and serum ferritin levels in patients with beta-major thalassemia in Al-Ihsan Regional Hospital Bandung and the relationship between the two. This was a cross-sectional study involving 50 thalassemia patients at Al-Ihsan Regional Hospital Bandung, which was chosen consecutively. We measure the adherence by the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire, filled out with the researcher’s guidance, while ferritin level data was obtained from the patient’s medical record. Data was collected in July–September 2019, and data were analyzed using chi-square test with the help of STATA software version 13. The results showed the majority of patients with beta-major thalassemia in Al-Ihsan Regional Hospital Bandung (60%, 45.4–72.9% CI) have a low level of compliance in the consumption of iron chelation drugs and most have serum ferritin levels >2.500 ng/mL (58%, 43.5–71.2 CI). There was a statistically significant relationship between the level of compliance with iron chelation drug consumption with serum ferritin levels in patients with beta-major thalassemia in Al-Ihsan Regional Hospital Bandung (p=0.00).


Keywords


Feritin; Kepatuhan minum obat; MMAS-8; Talasemia beta mayor; β-major thalassemia; drug adherence; ferritin; MMAS-8

Full Text:

PDF

References


Kumar V, Abbas AK, Aster JC, Robbins SL. Robbins basic pathology. Philadelphia, PA: Elsevier/Saunders; 2013.

Cappellini MD. 162 – The thalassemias. Goldman-Cecil Med. 2016:1089-1095.e2. doi:10.1016/B978-1-4557-5017-7.00162-8

Hoffbrand AV, Moss P, Hoffbrand AV. Hoffbrand’s essential haematology. Edisi ke-7. John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK. 2016.

Taher A, Nathan D, Porter J. Evaluation of iron levels to avoid the clinical sequelae of iron overload. Semin Hematol. 2007;44(SUPPL. 3):2-6. doi:10.1053/j.seminhematol.2007.03.002

Temraz S, Santini V, Musallam K, Taher A. Iron overload and chelation therapy in myelodysplastic syndromes. Crit Rev Oncol Hematol. 2014;91(1):64–73. doi:10.1016/j.critrevonc.2014.01.006

Health WE, Health O. Adherence to deferasirox among beta-thalassemia major children - a cross-sectional study in a tertiary care hospita. Indian J Child Heal. 2010;36(1):2016–9. doi:10.1089/ten.tea.2015.0461

Lukas S, Nugroho H, Ellora Sudarman V. Correlations between oral iron chelation therapy adherences with thalassemia children’s growth in Anna Medika Hospital. Sci Int (Lahore). 2018;30(2):247–52.http://www.sci-int.com/pdf/636579332591484419.edited=Aneela.pdf.

Tejasari RK, Reniarti L, Effendi SH. Faktor risiko hiperkoagulasi pada thalassemia anak. Sari Pediatr. 2016;16(6):427. doi:10.14238/sp16.6.2015.427-33

Yanitawati, Mardhiyah AI, Widianti E. Hubungan perilaku sakit dalam aspek psikososial dengan kualitas hidup remaja thalasemia. J Keperawatan BSI. 2017;5(1):38–47. http://ejournal.bsi.ac.id/ejurnal/index.php/jk 39.

Aji DN, Silman C, Aryudi C, Cynthia, Centauri, Andalia D, dkk. Faktor–faktor yang berhubungan dengan kualitas hidup pasien thalassemia mayor di Pusat Thalassemia Departemen Ilmu Kesehatan Anak RSCM. Sari Pediatr. 2009;11(2):85–9.

Arifna F, Ismy J, Yusuf H. Hubungan kepatuhan minum obat kelasi besi terhadap perkembangan seks sekunder pada anak penderita thalasemia beta mayor di Sentral Thalasemia RSUDZA Banda Aceh. J Ilm Mhs Medisia. 2017;2(3):13–17.

Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, dkk. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. Cochrane Database Syst Rev. 2018;2018(5). doi:10.1002/14651858.CD012349.pub2

Fadlyana E, Ma'ani F, Elizabeth M, Reniarti L. Correlation between serum ferritin level and growth disorders in children with thalassemia. Am J Clin Med Res. 2017;5(3):31–5. DOI: 10.12691/ajcmr-5-3-2.

Satria A, Ridar E, Tampubolon L. Hubungan derajat klinis dengan kadar feritin penyandang thalasemia β di RSUD Arifin Achmad. Jom Fk. 2016;3(2):1–9.

Taher AT, Saliba AN. Iron overload in thalassemia: Different organs at different rates. Hematology. 2017;2017(1):265–71. doi:10.1182/asheducation-2017.1.265

Guidelines for the Clinical Care of Patient with Thalassemia in Canada. [diunduh 13 April 2019]. Tersedia dari: http://www.thalassemia.ca/wp-content/uploads/Thalassemia-Guidelines_LR.pdf

Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, dkk. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. J Med Econ. 2016;19(3):292–303. doi:10.3111/13696998.2015.1117979




DOI: https://doi.org/10.29313/jiks.v2i1.5572

Refbacks

  • There are currently no refbacks.



eISSN: 2656-8438


View My Stats 


Flag Counter

Jurnal Integrasi Kesehatan dan Sains is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.